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Background
Hemagglutinin (HA) and neuraminidase (NA) are the
two major surface glycoproteins of influenza viruses and
the main targets of vaccine-induced antibodies (Abs).
While several broadly neutralizing Abs targeting con-
served epitopes in diverse HA subtypes have been iso-
lated, NA-specific Abs could only cross-protect partially
against homologous and heterologous strains from the
same subtype.
Materials and methods
Comprehensive bioinformatics analyses of all publicly
available full-length NA sequences using multiple align-
ments and Shannon entropy were conducted to identify
conserved sequences in all influenza A and B viral NA [1].
Growth kinetics of wild-type or recombinant viruses with
single alanine substitutions within the identified regions
was then analyzed in MDCK cells. A rabbit monoclonal
Ab (mAb), denoted as HCA-2, raised against one of the
characterized sequences was then examined for its in vitro
inhibitory effects and in vivo prophylactic efficacy against
several influenza A and B strains.
Results
Bioinformatics analyses uncovered a universally con-
served 9-mer peptide amongst all influenza NA proteins
(amino acids 222-230 and comprised of “ILRTQESEC”).
Substitutions within this universal epitope underscored
its crucial roles in viral fitness and replication [2].
Importantly, the HCA-2 mAb showed broad in vitro
inhibition against multiple strains from all influenza A
NA subtypes (N1-N9) and influenza B viruses from both
Victoria and Yamagata genetic lineages [3,4]. It also pro-
vided heterosubtypic protection in mice against lethal
doses of H1N1 and H3N2 strains. Finally, amino acid
residues I222 and E227, located in close proximity to
the active site, were found to be indispensable for inhi-
bition by this mAb [3,4].
Conclusions
These findings reveal the essential role of this unique
highly-conserved sequence in NA function and viral
replication and indicate that it is sufficiently exposed to
allow access by inhibitory antibody during the course of
infection. Thus, it could represent a potential target for
novel antivirals or targeted-vaccines against diverse
strains of influenza A and B viruses.
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